Last 47 quarters of trend data · Healthcare · Biotechnology
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | -0.06 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| P/S Ratio | — | — | — | — | — | — | — | — | — | — | — | — | — | — | 23.29 | 25.51 | 32.44 | 40.29 | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| P/B Ratio | 0.13 | 2.18 | 1.06 | 0.66 | 0.11 | 0.04 | 0.03 | 0.02 | 0.08 | 0.14 | 0.27 | 2.44 | 1.22 | 2.81 | 3.13 | 2.96 | 3.57 | 4.00 | 3.65 | 4.16 | 4.80 |
| — | +5438.6% | +3668.5% | +2947.0% | +40.7% | -71.5% | -89.6% | -99.1% | -93.8% | -95.1% | -91.4% | -17.6% | -65.8% | -29.8% | -14.4% | -28.9% | -25.6% | +58.2% | +13.6% | -2.2% | +115.0% | |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | — | — | — | — | — | — | — | — | — | — | — | — | — | — | -262.2% | -263.8% | -248.7% | -288.2% | — | 1273237.8% | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | -100.0% | — | — | — | +23078.8% | — | |
| Operating Margin | — | — | — | — | — | — | — | — | — | — | — | — | — | — | -509.7% | -515.5% | -513.8% | -557.4% | — | 2016293.4% | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | -100.0% | — | — | — | +19520.6% | — | |
| Net Margin | — | — | — | — | — | — | — | — | — | — | — | — | — | — | -503.0% | -341.9% | -513.8% | -557.2% | — | 2011719.2% | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | -100.0% | — | — | — | +19928.9% | — |
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -166.6% | -55.0% | -48.9% | -33.9% | -30.4% | -75.2% | -23.9% | -72.2% | -24.5% | -34.0% | -34.5% | -25.1% | -23.7% | -20.0% | -15.9% | -9.7% | -13.4% | -13.1% | -11.9% | -12.1% | -11.3% |
| — | +26.9% | -104.8% | +53.1% | -24.1% | -121.4% | +30.7% | -187.9% | -3.2% | -69.6% | -116.5% | -159.6% | -77.1% | -53.2% | -33.4% | +20.2% | -18.8% | -76.8% | -56.9% | -25.9% | -46.0% | |
| ROA | -104.2% | -28.6% | -29.4% | -22.6% | -20.4% | -44.7% | -13.4% | -50.8% | -19.0% | -26.0% | -26.1% | -19.4% | -19.0% | -16.8% | -9.4% | -5.7% | -10.9% | -10.9% | -10.2% | -10.4% | -10.0% |
| — | +36.1% | -118.8% | +55.4% | -7.0% | -71.9% | +48.5% | -162.3% | -0.3% | -55.1% | -176.7% | -236.7% | -73.6% | -53.1% | +7.8% | +44.9% | -9.5% | -62.6% | -47.6% | -20.0% | -41.0% | |
| ROIC | -193.9% | -83.1% | -73.6% | -43.3% | -33.6% | -48.0% | -55.5% | -108.1% | -24.6% | -25.0% | -25.4% | -23.0% | -21.7% | -17.5% | -12.9% | -12.5% | -12.0% | -12.7% | -16.8% | -13.5% | -13.9% |
| — | -73.0% | -32.5% | +59.9% | -36.5% | -91.9% | -118.8% | -370.8% | -13.5% | -43.1% | -96.0% | -83.1% | -81.5% | -37.3% | +22.8% | +7.5% | +14.0% | -46.8% | -79.2% | -67.1% | -109.9% |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.28 | 0.00 | 0.39 | 0.28 | 0.36 | 0.33 | 0.43 | 0.38 | 0.19 | 0.17 | 0.23 | 0.18 | 0.16 | 0.14 | 0.12 | 0.11 | 0.11 | 0.10 | 0.10 | 0.09 | 0.08 |
| — | -99.0% | -9.1% | -26.5% | +85.6% | +94.3% | +85.4% | +106.4% | +21.5% | +22.6% | +91.0% | +64.1% | +46.2% | +33.7% | +27.6% | +25.6% | +32.1% | +85.3% | +75.9% | +52.3% | +46.2% | |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Current Ratio | 2.79 | 0.85 | 1.32 | 2.79 | 3.78 | 4.07 | 3.35 | 3.01 | 5.53 | 6.39 | 5.15 | 5.93 | 6.19 | 9.27 | 14.88 | 8.06 | 7.57 | 7.79 | 11.97 | 11.73 | 13.78 |
| — | -79.2% | -60.4% | -7.5% | -31.6% | -36.2% | -35.0% | -49.2% | -10.7% | -31.1% | -65.4% | -26.4% | -18.2% | +19.0% | +24.3% | -31.3% | -45.1% | -54.1% | -57.9% | -32.0% | -40.0% | |
| Quick Ratio | 2.79 | 0.85 | 1.32 | 2.79 | 3.78 | 4.07 | 3.35 | 3.01 | 5.53 | 6.39 | 5.15 | 5.93 | 6.19 | 9.27 | 14.88 | 8.06 | 7.57 | 7.79 | 11.97 | 11.73 | 13.78 |
| — | -79.2% | -60.4% | -7.5% | -31.6% | -36.2% | -35.0% | -49.2% | -10.7% | -31.1% | -65.4% | -26.4% | -18.2% | +19.0% | +24.3% | -31.3% | -45.1% | -54.1% | -57.9% | -32.0% | -40.0% | |
| Interest Coverage | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 47 years · Updated daily
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying MTNB stock.
Matinas BioPharma Holdings, Inc.'s current P/E is -0.1x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking Matinas BioPharma Holdings, Inc.'s business trajectory between earnings reports.